Denali Therapeutics Inc (NASDAQ:DNLI) has been given an average broker rating score of 1.17 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy rating and two have assigned a strong buy rating to the company.

Analysts have set a twelve-month consensus price objective of $24.67 for the company and are anticipating that the company will post ($0.30) EPS for the current quarter, according to Zacks. Zacks has also assigned Denali Therapeutics an industry rank of 184 out of 265 based on the ratings given to its competitors.

DNLI has been the subject of several analyst reports. Morgan Stanley initiated coverage on shares of Denali Therapeutics in a research note on Tuesday, January 2nd. They issued an “overweight” rating and a $25.00 price target for the company. Evercore ISI initiated coverage on shares of Denali Therapeutics in a research note on Tuesday, January 2nd. They issued an “outperform” rating and a $23.00 price target for the company. Goldman Sachs Group initiated coverage on shares of Denali Therapeutics in a research note on Tuesday, January 2nd. They issued a “neutral” rating for the company. Finally, JPMorgan Chase & Co. initiated coverage on shares of Denali Therapeutics in a research note on Tuesday, January 2nd. They issued an “overweight” rating and a $24.00 price target for the company.

In other news, major shareholder Douglas K. Bratton purchased 275,000 shares of the company’s stock in a transaction dated Tuesday, December 12th. The stock was acquired at an average price of $18.00 per share, with a total value of $4,950,000.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Several hedge funds have recently modified their holdings of DNLI. Crestline Management LP acquired a new position in shares of Denali Therapeutics in the 4th quarter worth approximately $321,782,000. Flagship Pioneering Inc. acquired a new position in shares of Denali Therapeutics in the 4th quarter worth approximately $139,489,000. Artal Group S.A. acquired a new position in shares of Denali Therapeutics in the 4th quarter worth approximately $7,820,000. Bamco Inc. NY acquired a new position in shares of Denali Therapeutics in the 4th quarter worth approximately $7,664,000. Finally, Bridger Management LLC acquired a new position in shares of Denali Therapeutics in the 4th quarter worth approximately $4,888,000. Hedge funds and other institutional investors own 0.06% of the company’s stock.

Shares of Denali Therapeutics (DNLI) opened at $20.93 on Monday. Denali Therapeutics has a one year low of $14.72 and a one year high of $24.02.

WARNING: “Brokerages Set $24.67 Target Price for Denali Therapeutics Inc (DNLI)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2018/02/15/brokerages-set-24-67-target-price-for-denali-therapeutics-inc-dnli.html.

About Denali Therapeutics

Denali Therapeutics Inc is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease.

Get a free copy of the Zacks research report on Denali Therapeutics (DNLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.